 |
|
|
|
 |
|
|
| Article 1 to 4 out of 4 concerning Xanthus Pharmaceuticals, Inc.
|
-
Antisoma to acquire Boston-based Xanthus Pharmaceuticals
(05/20/2008)
Antisoma plc announced that it has entered into an agreement to acquire private US oncology company Xanthus Pharmaceuticals, Inc. in an all-share deal valued at GBP 26.8 million (USD 52.2 million). Simultaneously, Antisoma has executed a fundraising ...
-
Xanthus acquires from John Hopkins University exclusive license to patent estate covering FLT3 pathway
(04/13/2007)
Xanthus Pharmaceuticals, Inc. announced that the company has acquired an exclusive worldwide license to a patent estate from Johns Hopkins University for treating immune-related disorders by inhibiting the FLT3 tyrosine kinase. FLT3 is highly ...
-
Xanthus Presents In Vitro Data Demonstrating that Symadex is a Potent and Selective Inhibitor of FLT3
(09/20/2006)
Xanthus Pharmaceuticals, Inc. presented data from a study in which Symadex (C-1311) was identified as a potent, selective inhibitor of the receptor tyrosine kinase (RTK), FLT3. Researchers from Xanthus and the Medical University of South Carolina, ...
-
Xanthus' Symadex shows Remyelination in Multiple Sclerosis Animal Model
(02/14/2006)
Xanthus Life Sciences, Inc., announced that data from a study conducted with a Multiple Sclerosis (MS) animal model demonstrated that Symadex(TM) permitted remyelination by prevention of inflammatory cell infiltration. Stephen J. Karlik, Ph.D., ...
Additional information
Xanthus Pharmaceuticals, Inc.
Cambridge, MA, United States of America
Company
|
|
|
|
|
|
Top
